MVCD2
MCID: MCR112
MIFTS: 42

Microvascular Complications of Diabetes 2 (MVCD2)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases

Aliases & Classifications for Microvascular Complications of Diabetes 2

MalaCards integrated aliases for Microvascular Complications of Diabetes 2:

Name: Microvascular Complications of Diabetes 2 57 74 29 13 6 40
Proliferative Diabetic Retinopathy 74 72
Diabetic Nephropathy 74 72
Mvcd2 57 74
Microvascular Complications of Diabetes, Susceptibility to, 2 57
Proliferative Retinopathy, Diabetic, Susceptibility to 57
End-Stage Renal Disease, Diabetic, Susceptibility to 57
Proliferative Retinopathy, Diabetic 57
End-Stage Renal Disease, Diabetic 57
Diabetic End-Stage Renal Disease 74

Classifications:



External Ids:

MeSH 44 D048909
UMLS 72 C0011881 C0154830

Summaries for Microvascular Complications of Diabetes 2

UniProtKB/Swiss-Prot : 74 Microvascular complications of diabetes 2: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 2, also known as proliferative diabetic retinopathy, is related to background diabetic retinopathy and microvascular complications of diabetes 1. An important gene associated with Microvascular Complications of Diabetes 2 is EPO (Erythropoietin). The drugs Methylcobalamin and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include endothelial, eye and kidney.

More information from OMIM: 612623 PS603933

Related Diseases for Microvascular Complications of Diabetes 2

Diseases in the Microvascular Complications of Diabetes 5 family:

Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 2
Microvascular Complications of Diabetes 3 Microvascular Complications of Diabetes 4
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 492)
# Related Disease Score Top Affiliating Genes
1 background diabetic retinopathy 12.0
2 microvascular complications of diabetes 1 12.0
3 microvascular complications of diabetes 3 12.0
4 vitreoretinopathy, neovascular inflammatory 11.9
5 severe nonproliferative diabetic retinopathy 11.9
6 microvascular complications of diabetes 7 11.8
7 retinal detachment 11.1
8 macular retinal edema 10.9
9 macular holes 10.9
10 renal fibrosis 10.9
11 neovascular glaucoma 10.8
12 diabetic macular edema 10.7
13 vitreoretinopathy 10.7
14 glomerulonephritis 10.7
15 hydrops, lactic acidosis, and sideroblastic anemia 10.7
16 nephrotic syndrome 10.6
17 rubeosis iridis 10.6
18 retinal ischemia 10.6
19 cataract 10.6
20 eye disease 10.5
21 retinal disease 10.5
22 uremia 10.5
23 end stage renal failure 10.5
24 hypertension, essential 10.5
25 iga glomerulonephritis 10.5
26 hyperglycemia 10.5
27 microvascular complications of diabetes 4 10.5
28 microvascular complications of diabetes 6 10.5
29 intraocular pressure quantitative trait locus 10.5
30 vitreous detachment 10.5
31 endophthalmitis 10.4
32 membranous nephropathy 10.4
33 uveitis 10.4
34 neuroretinitis 10.4
35 retinitis 10.4
36 glomerular disease 10.4
37 kidney hypertrophy 10.4
38 preretinal fibrosis 10.4
39 retinal vascular disease 10.4
40 hyperinsulinism 10.4
41 atherosclerosis susceptibility 10.3
42 nephrosclerosis 10.3
43 hyperuricemia 10.3
44 diabetes mellitus, noninsulin-dependent 10.3
45 retinitis pigmentosa 10.3
46 insulin-like growth factor i 10.3
47 retinoschisis 1, x-linked, juvenile 10.3
48 rapidly involuting congenital hemangioma 10.3
49 proteasome-associated autoinflammatory syndrome 1 10.3
50 muscle hypertrophy 10.3

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 2:



Diseases related to Microvascular Complications of Diabetes 2

Symptoms & Phenotypes for Microvascular Complications of Diabetes 2

Clinical features from OMIM:

612623

Drugs & Therapeutics for Microvascular Complications of Diabetes 2

Drugs for Microvascular Complications of Diabetes 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 431)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
2
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
3
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
4
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
5
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
6
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
7
Atenolol Approved Phase 4 29122-68-7 2249
8
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
9
Methyldopa Approved Phase 4 555-30-6 38853
10
Clonidine Approved Phase 4 4205-90-7 2803
11
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
12
Capsaicin Approved Phase 4 404-86-4 1548943
13
Bevacizumab Approved, Investigational Phase 4 216974-75-3
14
Dipivefrin Approved Phase 4 52365-63-6 3105
15
Ranibizumab Approved Phase 4 347396-82-1 459903
16
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
17
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
18
Povidone-iodine Approved Phase 4 25655-41-8
19
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
20
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
21
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
22
Probucol Approved, Investigational Phase 4 23288-49-5 4912
23
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 130881 158781
24
Ramipril Approved Phase 4 87333-19-5 5362129
25
Doxazosin Approved Phase 4 74191-85-8 3157
26
Indapamide Approved Phase 4 26807-65-8 3702
27
Atorvastatin Approved Phase 4 134523-00-5 60823
28
Trandolapril Approved Phase 4 87679-37-6 5484727
29
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
30
Nisoldipine Approved Phase 4 63675-72-9 4499
31
Insulin glargine Approved Phase 4 160337-95-1
32
Insulin glulisine Approved Phase 4 207748-29-6
33
Liraglutide Approved Phase 4 204656-20-2 44147092
34
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
35
Allopurinol Approved Phase 4 315-30-0 2094
36
Nitric Oxide Approved Phase 4 10102-43-9 145068
37
Insulin Lispro Approved Phase 4 133107-64-9
38
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723 149351
39
Glimepiride Approved Phase 4 93479-97-1 3476
40
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
41
Febuxostat Approved Phase 4 144060-53-7 134018
42
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
43
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
44
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
45
Amlodipine Approved Phase 4 88150-42-9 2162
46
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
47
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
48
Terazosin Approved Phase 4 63590-64-7 5401
49
Hydralazine Approved Phase 4 86-54-4 3637
50
Gliclazide Approved Phase 4 21187-98-4 3475

Interventional clinical trials:

(show top 50) (show all 588)
# Name Status NCT ID Phase Drugs
1 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
2 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
3 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
4 Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
5 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
6 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
7 Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy Unknown status NCT01824043 Phase 4 intravitreal ranibizumab injections
8 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
9 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Unknown status NCT03147677 Phase 4 Alfacalcidol;Irbesartan
10 Effects of Glatiramer Acetate (Copaxone) in the Nerve Fiber Layer Thickness and Retinal Function in Diabetic Patients After Pan- Retinal Photocoagulation (PRP), a Double- Masked Randomized Clinical Trial. Unknown status NCT00677664 Phase 4 Glatiramer acetate (Copaxone);Mannitol
11 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
12 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
13 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
14 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
15 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
16 A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study Unknown status NCT01306981 Phase 4 Ranibizumab;Saline
17 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
18 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
19 Safety of Add on Aliskiren to ACEI and ARB Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
20 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
21 A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy Unknown status NCT02314533 Phase 4 fenofibrate
22 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
23 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study Unknown status NCT02690883 Phase 4 Exenatide;Lispro
24 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
25 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
26 A Study on the Anti-proteinuric Effects of Pioglitazone in Patients With Type 2 Diabetes. Unknown status NCT00749047 Phase 4 Pioglitazone
27 Comparison Between ARB and ARB Plus CCB on Incidence of Renal and Cardiovascular Events in Hypertensive ADPKD Patients Unknown status NCT00541853 Phase 4 Candesartan;Candesartan and Cilnidipine;Candesartan plus non-CCB agents
28 Phase IV, Effect of Rennin-Angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria--- A Randomized Controlled Trial Unknown status NCT01500590 Phase 4 Renin-angiotensin system blockers;non-renin angiotensin system blockers
29 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
30 The Reduction of Microalbuminuria in Japanese Hypertensive Subjects With Type 2 Diabetes Mellitus Treated With Valsartan or Amlodipine: Study Design for the Shiga Microalbuminuria Reduction Trial (SMART) Unknown status NCT00202618 Phase 4 Valsartan;Amlodipine
31 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Unknown status NCT00535925 Phase 4 current therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
32 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
33 The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
34 Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy Completed NCT01025934 Phase 4 Bevacizumab
35 Pain Using Reduced Fluence Parameters in Photocoagulation for Diabetic Retinopathy. Completed NCT00802269 Phase 4
36 Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation Completed NCT01724385 Phase 4 intravitreal injection of bevacizumab
37 Prevention of Post-Photocoagulation Macular Edema by Intravitreal Bevacizumab. Completed NCT00801866 Phase 4 Bevacizumab
38 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
39 Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy Completed NCT01854593 Phase 4 Bevacizumab
40 Effect of Adjunctive Intravitreal Bevacizumab Before Panretinal Photocoagulation in Macular Thickness and Retinal Nerve Fiber Layer Thickness Completed NCT01504724 Phase 4 bevacizumab
41 A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4 Probucol;Probucol and Cilostazol
42 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
43 Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4 Effects of doxazosin on morning surge in diabetic patients
44 Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
45 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil;Candesartan Cilexetil 32mg
46 A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy Completed NCT00234871 Phase 4 trandolapril/verapamil;Lotrel (amlodipine/benazepril)
47 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4 nisoldipine;lisinopril
48 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4
49 "Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study" Completed NCT01028287 Phase 4 ACTH;ACTH
50 A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients Completed NCT01664676 Phase 4 Liraglutide;Placebo-liraglutide

Search NIH Clinical Center for Microvascular Complications of Diabetes 2

Inferred drug relations via UMLS 72 / NDF-RT 51 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan

Genetic Tests for Microvascular Complications of Diabetes 2

Genetic tests related to Microvascular Complications of Diabetes 2:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 2 29 EPO

Anatomical Context for Microvascular Complications of Diabetes 2

MalaCards organs/tissues related to Microvascular Complications of Diabetes 2:

41
Endothelial, Eye, Kidney, Retina, Pancreas, Monocytes, Heart

Publications for Microvascular Complications of Diabetes 2

Articles related to Microvascular Complications of Diabetes 2:

(show top 50) (show all 3827)
# Title Authors PMID Year
1
Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. 38 8 71
18458324 2008
2
Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. 38 8
16120858 2005
3
MicroRNAs as biomarkers of diabetic retinopathy and disease progression. 38
31290435 2019
4
Diabetes induces IL-17A-Act1-FADD-dependent retinal endothelial cell death and capillary degeneration. 38
31239234 2019
5
Leucine-rich α-2-glycoprotein predicts proliferative diabetic retinopathy in type 2 diabetes. 38
31256924 2019
6
PHOTOCOAGULATION VERSUS RANIBIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Should Baseline Characteristics Affect Choice of Treatment? 38
30807516 2019
7
Effect of intravitreal conbercept treatment on the expression of Long Noncoding RNAs and mRNAs in Proliferative Diabetic Retinopathy Patients. 38
30900812 2019
8
Screening eye exams in youth with type 1 diabetes under 18 years of age: Once may be enough? 38
31206973 2019
9
EVALUATION OF MULTISPECTRAL IMAGING IN DIAGNOSING DIABETIC RETINOPATHY. 38
29901495 2019
10
The effect of hyperbaric oxygen therapy on retinal thickness and progression of retinopathy in patients with Type 2 diabetes: a prospective cohort study. 38
31010336 2019
11
SCF (Stem Cell Factor) and cKIT Modulate Pathological Ocular Neovascularization. 38
31434494 2019
12
Enantioselective Synthesis of Homoisoflavanones by Asymmetric Transfer Hydrogenation and Their Biological Evaluation for Antiangiogenic Activity. 38
31381339 2019
13
OCT angiography-based monitoring of neovascular regression on fibrovascular membrane after preoperative intravitreal conbercept injection. 38
31053944 2019
14
Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions. 38
30878488 2019
15
A cross-sectional study of vitreous and serum high mobility group box-1 levels in proliferative diabetic retinopathy. 38
31421026 2019
16
Optical coherence tomography angiography of foveal neovascularisation in proliferative diabetic retinopathy. 38
31434675 2019
17
Role of miR-21 in rats with proliferative diabetic retinopathy via TGF-β signaling pathway. 38
31389569 2019
18
Expression and significance of MiR-126 and VEGF in proliferative diabetic retinopathy. 38
31378876 2019
19
Widefield Swept-Source Optical Coherence Tomography Angiography of Proliferative Diabetic Retinopathy. 38
31415693 2019
20
Risk factors for prevalent diabetic retinopathy and proliferative diabetic retinopathy in type 1 diabetes. 38
31407162 2019
21
Interleukin-11 Overexpression and M2 Macrophage Density are Associated with Angiogenic Activity in Proliferative Diabetic Retinopathy. 38
31403827 2019
22
MicroRNA-423 may regulate diabetic vasculopathy. 38
31422516 2019
23
Effect of prior glaucoma surgery on intraocular pressure immediately after anti-vascular endothelial growth factor injection. 38
31388743 2019
24
Metalloproteinases mediate diabetes-induced retinal neuropathy and vasculopathy. 38
31183508 2019
25
The diagnostic accuracy of an intelligent and automated fundus disease image assessment system with lesion quantitative function (SmartEye) in diabetic patients. 38
31412800 2019
26
MiR-203a-3p inhibits retinal angiogenesis and alleviates proliferative diabetic retinopathy in oxygen-induced retinopathy (OIR) rat model via targeting VEGFA and HIF-1α. 38
31408201 2019
27
Endothelial cell density changes in diabetic and nondiabetic eyes undergoing phacoemulsification employing phaco-chop technique. 38
30056522 2019
28
Retinal Blood Velocity and Flow in Early Diabetes and Diabetic Retinopathy Using Adaptive Optics Scanning Laser Ophthalmoscopy. 38
31382617 2019
29
The effect of the duration of diabetes on dry eye and corneal nerves. 38
31029535 2019
30
Nonlinearities in the flicker electroretinogram: A tool for studying retinal dysfunction applied to early-stage diabetic retinopathy. 38
31129287 2019
31
Intravitreal neurodegenerative and inflammatory mediators in proliferative diabetic retinopathy. 38
30970121 2019
32
Safety and efficacy of intravitreal conbercept injection after vitrectomy for the treatment of proliferative diabetic retinopathy. 38
30872770 2019
33
Comprehensive analysis of vitreous humor chemokines in type 2 diabetic patients with and without diabetic retinopathy. 38
30911832 2019
34
Retinal vascular abnormalities in Sturge-Weber syndrome. 38
31238475 2019
35
Evaluation of Circulating Plasma VEGF-A, ET-1 and Magnesium Levels as the Predictive Markers for Proliferative Diabetic Retinopathy. 38
31391728 2019
36
Therapeutic effect of lutein supplement on non-proliferative diabetic retinopathy: A retrospective study. 38
31335666 2019
37
Serum and vitreous resistin levels in patıents with proliferative diabetic retinopathy. 38
31362052 2019
38
Vascular Endothelial Growth Factor in the Vitreous of Proliferative Diabetic Retinopathy Patients: Chasing a Hiding Prey? 38
31221704 2019
39
Galectin-1 studies in proliferative diabetic retinopathy. 38
31318490 2019
40
Elevation of the vitreous body concentrations of oxidative stress-responsive apoptosis-inducing protein (ORAIP) in proliferative diabetic retinopathy. 38
31062144 2019
41
Assessment of Choroidal Thickness Inside and Outside of Vascular Arcade in Diabetic Retinopathy Eyes Using Spectral-Domain Optical Coherence Tomography. 38
31346253 2019
42
Automated Quantification of Hyperreflective Foci in SD-OCT with Diabetic Retinopathy. 38
31329137 2019
43
The effect of panretinal photocoagulation on confocal laser scanning ophthalmoscopy and stereo photographic parameters of optic disk topography in patients with diabetic retinopathy. 38
31038552 2019
44
Clinical characteristics of Japanese diabetic patients with critical limb ischemia presenting Fontaine stage IV. 38
31275791 2019
45
Serum Pentraxin 3 level as a recent biomarker of diabetic retinopathy in Egyptian patients with diabetes. 38
31405644 2019
46
Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases. 38
31358777 2019
47
Long term features of diabetic retinopathy in streptozotocin-induced diabetic Wistar rats. 38
31028750 2019
48
Beneficial visual outcome of vitrectomy and delamination surgery for tractional complications of diabetic retinopathy in a cohort of black patients. 38
31270465 2019
49
Upregulated VEGF and Robo4 correlate with the reduction of miR-15a in the development of diabetic retinopathy. 38
30980286 2019
50
STAT3 activation in circulating myeloid-derived cells contributes to retinal microvascular dysfunction in diabetes. 38
31286987 2019

Variations for Microvascular Complications of Diabetes 2

ClinVar genetic disease variations for Microvascular Complications of Diabetes 2:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 EPO NM_000799.3(EPO): c.-1306C> A single nucleotide variant risk factor rs1617640 7:100317298-100317298 7:100719675-100719675

Expression for Microvascular Complications of Diabetes 2

Search GEO for disease gene expression data for Microvascular Complications of Diabetes 2.

Pathways for Microvascular Complications of Diabetes 2

GO Terms for Microvascular Complications of Diabetes 2

Sources for Microvascular Complications of Diabetes 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....